Types | DnaRegion
|
Roles | Device
engineered_region
|
Sequences | BBa_K2008005_sequence (Version 1)
|
Description
This part contains an active nonamer from the Bowman Birk Protease Inhibitor (BBI) with the addition of lysine, serine, cysteine, and isoleucine (KSCI) tag on the N-terminal end and a phenylalanine (F) tag on the C-terminal end to increase BBI solubility. A B. subtilis secretory signal peptide sequence is included to allow for secretion of the peptide directly into surrounding media. A transdermal tag (TD1, BBa_K1074000) is fused to the N-terminus of BBI to allow for diffusion of the peptide across the skin.
This coding sequence is under the control of the constitutive B. subtilis promoter pVeg (BBa_K143012) and a strong B. subtilis RBS (BBa_K780001).
Note: This part is a composite part, not a basic part, but it could not be entered as composite at this time.
Notes
Bacillus subtilis-specific components were used (strong RBS and constitutive promoter) to produce high levels of expression of the BBI peptide. A secretory signal peptide sequence was included to allow for secretion of the peptide directly into surrounding media. A transdermal tag allowed for diffusion of the peptide across the skin. Codons were optimized for B. subtilis. Additional amino acids were included to increase solubility of the desired peptide product.
Source
Members of the lentil family produce the full BBI protein, and the genetic sequence for the peptide was sourced originally from genomic DNA.